Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
863 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05969041 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors(MYE Symphony) | recruiting | Phase 1 | 48 | Myeloid TherapeuticsINDUSTRY | 1 | Jan 18, 2024 | clinicaltrials |
| NCT01281735 | International Chronic Myeloid Leukemia Pediatric Study(ICMLPed) | recruiting | — | 750 | Poitiers University HospitalOTHER | 20 | Jan 17, 2024 |
| clinicaltrials |
| NCT05833763 | A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.(GOlDiLOX) | recruiting | Phase 2 | 42 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05923008 | A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 182 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 29, 2023 | clinicaltrials |
| NCT02193841 | Simple Bone Cysts in Kids(SBoCK) | recruiting | Phase 3 | 160 | The Hospital for Sick ChildrenOTHER | 4 | Jul 12, 2023 | clinicaltrials |
| NCT05570227 | Metabolic Phenotypes in Melanoma(MetaMel) | recruiting | N/A | 240 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT04920617 | DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(VITALIZE) | recruiting | Phase 2 | 102 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 10 | Apr 7, 2023 | clinicaltrials |
| NCT04903782 | Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer(PREDICT) | recruiting | — | 270 | Sydney Children's Hospitals NetworkOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT05025813 | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma(DESQUAMATE) | recruiting | Phase 2 | 27 | Queensland HealthOTHER_GOV | 1 | Aug 1, 2022 | clinicaltrials |
| NCT04455932 | HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation | recruiting | N/A | 476 | Concord Repatriation General HospitalOTHER | 2 | Sep 8, 2021 | clinicaltrials |
| NCT01704716 | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | recruiting | Phase 3 | 3,300 | St. Anna KinderkrebsforschungOTHER | 20 | Oct 23, 2020 | clinicaltrials |
| NCT03838718 | REtroperitoneal SArcoma Registry: an International Prospective Initiative(RESAR) | recruiting | — | 2,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 11 | Feb 12, 2019 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials